Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)

NCT02631551 is registered in ClinicalTrials.gov with Glenmark Specialty S.A. as lead sponsor.

NCT NCT02631551
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02631551 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)
Lead sponsor
Glenmark Specialty S.A.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2016
Completion date
July 31, 2016
Enrollment
1,180 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

seasonal allergic rhinitis